

I. AMENDMENTS

Please amend claims 12 and 27 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

12. (Amended) A vaccine comprising a reassortant [reassortant virus] influenza A virion, the [virus] virion further comprising: a polynucleotide coding for the surface protein HA and a polynucleotide coding for the surface protein NA, each of HA and NA of a selected wild type influenza virus; a polynucleotide coding for PB1; a polynucleotide coding for PA; and a polynucleotide coding for M, each of PB1, PA and M of a selected cold-adapted influenza virus; and a polynucleotide coding for PB2 which consists of the sequence of SEQ ID NO 15; the polynucleotides being operatively linked to allow packaging of the reassorted polynucleotides into the virion [each other].

27. (Amended) A vaccine comprising a reassortant [virus] influenza A or B virion comprising the nucleic acid [sequence] of Claim 25 and a pharmaceutically acceptable carrier.

II. REMARKS

Claims 1, 4, 5, 7, 8, 12, 19, 20, 22, 23, and 25-27 are pending in the subject application. Claims 2, 3, 6, 9 and 11 previously were canceled without prejudice or disclaimer. Claims 1, 4, 5, 7, 8, 19, 20, 22, 25 and 26 have been withdrawn from examination as a result of a requirement for restriction. Claims 12, 23, and 27 are presently under examination.

Claims 12 and 27 are amended. Support for the amendment to claim 12 is found on page 5, lines 27 to 33. Amended claim 27 is supported in claim 1 and on page 4, lines 10 to 21 and page 23, line 16 to page 26, lines 34. The amendments to the claims is not intended to be a